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 Atypical Teratoid Rhabdoid Tumor (AT/RT) is a rare type of pediatric brain tumor that 
most commonly affects children under the age of 3. Being that the people who are primarily 
affected by this disease are so young, current treatments such as chemotherapy and radiation are 
not very effective at treating this cancer giving a bleak survival rate of less than 10%.  More than 
95% of patients with AT/RT are missing or severely lacking a protein from the SWI/SNF 
complex, INI-1, although the function of this protein is still unknown. There are several common 
truncations of INI-1 that are associated with AT/RT. Among the common truncations is the C-
terminal fraction, INI-1 (186-385). The goal of this project is to successfully clone this 200 
amino acid truncation into a vector so that the causation of AT/RT may be better understood. In 
order to clone, I first had to amplify the DNA using PCR, purify the product, perform restriction 
digests on both my gene of interest and the cloning vector, and successfully complete ligation 
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 Central Nervous System (CNS) Atypical Teratoid/ Rhabdoid Tumor (AT/RT) is a rare 
type of pediatric cancer in which tumors form on the brain and spinal cord. These tumors 
account for 1-2% of all pediatric brain tumors. This fast growing malignant tumor often proves 
deadly, having a depressing survival rate of less than 10% using current treatment options such 
as chemo-radiation and surgical removal. While the majority of people who have AT/RT are 
under the age of three years old, it can occur in older children and adults as well [1, 4]. By 
gaining a better understanding of this disease, and more importantly what some possible reasons 
are for it,  better treatment options could be produced, and in long term, maybe even a cure.   
  This disease has only been classified within the past 15-20 years. It is commonly 
misdiagnosed as Primitive Neuroectodermal Tumor (PNET), the most common type of pediatric 
brain tumors. With similar symptoms and appearance, immunohistochemistry can be done on 
removed sample of tissue to determine if it is AT/RT. Immunohistochemistry works by using 
antibodies to check for certain types of antigens in a sample. AT/RT can be determined by the 
lack of INI-1 protein [3].  
It has been observed that greater than 95% of all AT/RT cases lack all or part of the INI-1 
protein. This data establishes a potential link between INI-1 and AT/RT, and is the only strong 
correlation found thus far. The INI-1 protein works in a complex or group of proteins known as 
SWI/SNF [2].  Specifically, this protein complex is a chromatin remodeling complex which 
preforms multiple biological functions such as roles in genetic expression and DNA replication 
Sook4 
 
and repair.  Although this protein complex has been studied extensively, little is known about 
INI-1.  While the function, location within the complex, and appearance of this protein is still 
unknown, INI-1 has been observed to be absent, or seriously truncated in tumor cells among 
children with AT/RT, while all of SWI/SNF’s other proteins remain present. This information 
establishes a correlation between missing INI-1 proteins and AT/RT. 
Rationale for Study and Experimental Goal 
  
 While the observation has been made that INI-1 is absent of severely truncated in the 
majority of cases of AT/RT, it is not known whether or not the loss/ truncation of INI-1 causes 
the disease to occur and the tumors to grow, or if the disease causes the loss/truncation of INI-1. 
This cannot simply be “checked” as this would be an invasive procedure which is unnecessary in 
healthy individuals. So, by cloning known truncations, and using a full length INI-1 and an 
absent INI-1 as controls, we can eventually insert them into AT/RT tumor cells to see how the 
tumor and/or the INI-1 is effected, this question, along with other,  can be answered. 
 
Goal: My goal is to successfully clone the well-known truncation of INI-1 (186-385) into a 











 After thorough research on the topic of Atypical Teratoid/ Rhabdoid Tumor (AT/RT), 
and the protein INI-1, I chose a common truncation of amino acids 186-385 to work with. Using 
the National Center for Biotechnology Information (NCBI) website, I determined the nucleic 
acid base pairs which code for the INI-1 protein. I was then able to use the codons of these base 
pairs to translate this sequence into the amino acid sequence of full-length INI-1. From here, I 
cut out the amino acids 1-185, leaving me with my chosen truncation, amino acids 186-385 
(Figure 1; Appendix 1).  
 
Figure 1: Depiction of chosen truncation [INI-1(186-385)] as compared to full-length INI-1 
 
Primer Design and PCR 
 With the amino acid sequence for the truncation (186-385), I was able to use 
bioinformatics to design primers which would cut out my desired truncation from the full length 
sequence. A primer is a strand of nucleic acid that serves as a starting point for DNA synthesis. 
Primers used in laboratory techniques, such as polymerase chain reaction (PCR), are usually 
short, chemically synthesized oligonucleotides which are hybridized to target DNA, which is 
then copied by the polymerase. My primers consisted of the primer itself (18 base pairs shown in 
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red) and 3 nucleotides (shown in yellow) followed by a restriction site (6 base pairs shown in 
blue). My primers are as follows: Primer F, 5’-CGGGAATTCCTGGTCCCCATCCGGCTG-3’, 
which comes from the first 18 base pairs of the gene and has an EcoR1 restriction site, and 
Primer R, 5’-CGGGGATCCCCAGGCCGGGGCCGTGTT-3’, which comes from the last 18 
base pairs and has a BamH1 restriction site. The purpose of adding the restriction site onto the 
primer is for future use when cleaning up and digesting the protein. The gene of interest [INI-1 
(186-385)] does not have the specific sequence of these restriction sites, which ensures that the 
truncated gene will not be cut into smaller pieces. By adding the restriction site sequences to the 
5’ end of the primers, it is possible to cut the gene of interest out without losing any of the gene. 
After I had completed the design, I ordered the primers (For full primer design, see Appendix 1). 
 10X TAQ buffer, nanopure H2O, 10 mmol dNTPs, the two primers mentioned above, 0.1 
M MgCl2, and the DNA template for INI-1 were used in the PCR mixture. PCR was then run to 
cut the DNA and produce the fragment. This process, developed in 1983 by Kary Mullis, enables 
researches to produce millions of copies of a specific DNA sequence, a previously tedious 
process, in approximately 2 hours. Specific primers, the primer R and primer F mentioned above, 
are used to replicated target DNA. This reaction employs heat cycles to denature, apply primers, 
and essentially clone the desired DNA sequence.  
 Once PCR was complete, I inserted the amplified sample of truncated INI-1 and a Kb+ 
ladder into a 1.5% agarose gel made in TAE buffer and 2 µL of Ethidium Bromide (EtBr). BPB 
loading dye and nanopure water were added to the samples for loading and visibility purposes. 
This addition did not affect the length of the fragment. Gel electrophoresis, a method for the 
analysis and separation of DNA and other macromolecules and their fragments, was run for 
approximately half an hour (when the loading dye was visibly half way down the gel). By using 
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a Kb+ ladder as a guide, gel electrophoresis was used to determine the length of the DNA 
fragment obtained through PCR, which was expected to be 600 amino acids in length causing to 
show up just below the 650 line in the KB+ ladder (Figure 2).   
  
 
 Figure 2: 1.5% Agarose gel made with TAE and EtBR.  
 This gel was run at 140V for approximately 40 minutes. 
 
Isolation of PCR product 
 The PCR amplified DNA (450 uL) was cleaned and isolated using phenol extraction and 
ethanol precipitation. An equal volume of phenol was added to the PCR sample. This mixture 
was vortexed for 15 seconds, then placed in a centrifuge, balanced, and spun at 13,000 rotations 
per minute (rpm) for five minutes. The top layer was removed via micropipette and placed into a 
clean microfuge tube. Next, equal volumes of pre-made ½ phenol, ½ chloroform stock was 
added to the tube. This mixture was vortexed for 10 seconds and then placed in a balanced 
centrifuge. The tube was spun at 13,000 rpm for 5 minutes. The top layer was taken and placed 
in a clean microfuge tube via micropipette. An equal amount of chloroform was added and the 
mixture was vortexed for 10 seconds. This was again centrifuged at 13,000 rpm for 5 minutes. 
The top layer was removed and placed into a 1.5 mL microfuge tube. 1/10 of the total volume of 
1   2   3   4 
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3 M NaOA was measured and added to the tube. Once this was mixed, 2.5 volumes of 95% 
EtOH was added and mixed by inversion 8 times. The entire mixture was centrifuged at 13,000 
rpm for 15 minutes.  A pellet was formed in the bottom of the tube. The supernatant was 
removed. 500 uL of 70% ethanol was added. This mixture was centrifuges at 13,000 rpm for 10 
minutes. The supernatant was removed and it was again centrifuged at 13,000rpm for 1 minute. 
Remaining EtOH was removed from the tube and 30 uL of sterile water was added to re-suspend 
the pellet. Isolated DNA was NanoDropped and ran on a 1.5% agarose gel made with TAE. The 
NanoDropped sample was a concentration of 593.6 ng/uL with a 260/280 of 1.63 meaning that 
the sample was concentrated enough, and pure enough to go on. The gel showed the purified 
PCR to be just below the 650 bp mark in the Kb+ latter and therefore, it was assumed that the 
band was just as expected in the purified PCR sample, right at 600 bp. 
Restriction Digest 
 Restriction Digests are done in preparation of traditional cloning. Before I began my 
restriction digest I tested the enzymes to ensure that they were cutting properly, and tested the 
vector which was selected to clone into. The restriction enzymes which I used were EcoR1 and 
BamH1 (Figure 3; Figure 4). Restriction enzymes are used to cut DNA. They can yield two 
different types of cuts which would yield either sticky ends (as shown in figure 2 and 3) or blunt 
ends. They cut at a 6 amino acid restriction site which is specific to each enzyme.  The chosen 
vector, which I will clone into is pBABEpuro. This is a vector which is engineered with multiple 























Figure 5: pBABEpuro vector; Figure was derived using Google Images [6]. 
  
 Restriction digest was performed on both the amplified, truncated INI-1 (187-385) and 
the vector (pBABE). 10 uL of INI-1 was placed in tube one with 1.5 uL of BSA, 1.5 uL of 10X 
buffer 4, 1.0 uL of Bam-HI, and 1.0 uL of EcoR1. Tube 2 consisted of 10 uL of pBABE diluted 
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to 100 ng/uL, 1.5 uL of 10X Buffer 4, 1.0 uL of BamH1, and 1.0 uL of EcoR1. The entire 
procedure was done on ice, and ezymes were kept on ice throughout this experiment. Both tubes 
were incubated in a hot water bath at 37 ̊ C for one hour and heat killed for 20 minutes at 80 ̊ C to 
inactivate the BamH1 enzyme.  
 The vector, pBABE was not cleaned like the PCR sample, after it was heat inactivated 
and NanoDropped, it was stored in the -20 ̊ C freezer until needed for ligation. The NanoDrop 
showed that the digested pBABE had a 260/ 280 value of 0.72. While this is low, I suspect it is 
due to the proteins still in solution as it was not cleaned up.  INI-1 was cleaned up using gel 
filtration. 
Agarose Gel Purification 
 In gel filtration, the agarose gel cannot use EtBr as a stain because it is too harsh and will 
denature DNA. Since in gel purification the DNA band of interest is cut out in order to harvest 
the DNA, SYBR safe will be used as the staining agent for the gel in place of EtBr. A 1% 
agarose gel using TAE and 3 uL of SYBR safe was used for this procedure (Figure 7). In order 
to have a large well for the band of interest since the band will be harvested from the gel, tape 
was used on the comb (Figure 6). 
 





Figure 7:1% agarose gel made with TAE and SYBR Safe; Gel was run at 140V for 40 minutes 
  
 The band containing INI-1 
was carefully cut under UV light 
(Figure 7). The band was then 
sliced into small pieces and placed 
into the gel purification apparatus 
(Figure 8). Once the cut band was 
placed into the blue insert, the cap was placed on, and the entire apparatus was place into the 
centrifuge using an empty microfuge tube as a balance. This was spun for 15 minutes at 3,000 rpm. 
The low rpm was to ensure that the gel remained in the top compartment and did not escape into 
the tube through the filter. The 1.5 mL centrifuge tube was removed, capped, and labeled 
“supernatant 1.” A new tube was placed at the bottom of the apparatus and 50 mL of TAE was 
added to the top blue compartment. This was once again spun down at 3,000 rpm for 15 minutes 
         Figure 8: Gel Purification apparatus 
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to ensure that all the DNA was extracted from the gel. This tube was capped and labeled 
“supernatant 2.”  The NanoDropped Supernatant 1 yielded 28.4 ng/uL. Gel-purified pBABE which 
had been previously successful in cloning was also NanoDropped to be used in ligation and was 
measured at 28.4 ng/uL. The tubes were stored at -20 ̊ C to await ligation. 
Ligation 
 Ligation is a temperature sensitive cycle which employs the enzyme ligase to glue cut 
DNA back together. This enzyme is manipulated and used in the lab in cloning as it helps to glue 
a gene of interest into a vector.  
 Using the NEBio Ligation Calculator, dilutions for ligations were calculated. Tube 
contents can be seen in Table 1. 
 Tube 1 Tube 2 Tube 3 Tube 4 
pBABE 2.0 1.0 3.0 2.0 
INI-1 2.0 3.0 1.0 --- 
Autoclaved Water 4.0 4.0 4.0 6.0 
Ratio 
(vector:insert) 
1:1 1:3 3:1 control 
Table 1: Ligation dilutions and tube contents. All amounts are given in uL. 
 All tubes were tapped to mix and placed in water bath to incubate at 65 ̊ C for 5 minutes. 
After incubation, tubes were cooled at room temperature for 5 minutes. 10X ligation buffer was 
warmed to 45 ̊ C for a few minutes to ensure that it all was in solution. 1 uL of 10X ligation 
buffer and 1 uL of T4 DNA Ligase were added to each tube. Tubes were tapped to mix and sat at 





 Transformation is a very temperature sensitive processes which is used to introduce 
vectors into competent bacteria cells. Competent cells are E. coli cells which are able to take up 
exogenous DNA (7). They are very important in transformation because they can be manipulated 
by cooling and heat shocking which causes them to take up DNA which can then be plated on 
agar plates. 
 T1 T2 T3 T4 Control 
Ligated 5.0 5.0 5.0 5.0 1 ul conc. pBABE+4ul Autoclaved Water 
DH5α 
(Competent Cells) 
20. 20. 20. 20. 20. 
Table 2: Transformation tubes (number correlate to the tubes previously listed in table 1). Amounts listed in the 
table are measured in uL. 
 Transformation of all 5 tubes listed in Table 2 (T1, T2, T3, T4, and Control) were iced 
for 30 minutes, heated for one minute at 42 ̊ C (heat-shock), and then iced for 3 minutes. 200 uL 
of Luria Broth (LB) was added to each tube and mixed by flicking.  Tubes were plated on Agar + 
Ampicillin (AMP) plates labeled to correspond to each tube using aseptic technique. Ampicillin 
was added to the plates to ensure that bacteria who did not take up the vector could not survive 
and thrive. Bacteria which did contain the vector had a resistance to the antibiotic ampicillin 
because of the AMP resistant gene in pBABE. This allowed competent bacteria which took in 
the vector to able to make colonies. By using antibiotic and the engineered antibiotic resistance 
gene in the cloning vector, successful transformations can be differentiated from unsuccessful 
transformations allowing me to know which transformation could contain my gene of interest. 
Plates were incubated upside down at 37 ̊ C for 24 hours.  
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 After 24 hours colonies were assessed and counted. As expected, the positive control 
with consisted only of uncut pBABE and water yielded a lawn of colonies, and the negative 
ligation control yielded few colonies. This showed that the transformation was successful and 
that there was a little background of either uncut pBABE or rejoined pBABE which did not 
contain the gene of interest. However the other plates contained very few colonies (Figure 9). 
 
Figure 9: Agar+AMP plates after 24 hours T4 plate served as the negative control and served as “background,” meaning that it 
showed the number of colonies which could simply be ligated pBABE on the other plates, having no insert. The control plate 
served as the positive control which showed that the transformation was successful. 
 With so few colonies, the colony growth on plates T1, T21, and T3 did not meet the 
expectations that I had. I thought that I would have more than one plate which produced more 
colonies than that of the negative control since the negative control account for any 
“background,” or pBABE that does not contain the gene of interest (my INI-1 truncation). This 
was only the case on one plate which contained 7 colonies, giving reason to believe that 2 may 
contain the gene of interest. Despite my unexpected results, I continued on, harvesting all 9 
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possible colonies. The colonies were stuck with clean, autoclaved micropipette tips under ascetic 
conditions, and placed into tubes each containing 5mL of LB+AMP. Tubes were labeled 1-9, and 
placed in an incubator, shaking at 37 ̊ C for 24 hours. When tubes were removed from the 
incubator, 1.5 mL from each tube was transferred into clearly labeled microfuge tubes and spun 
down in the centrifuge at 4,000 rpm for 4 minutes. A pellet of bacteria formed in the bottom. 
Supernatant, which did not contain the DNA, was removed.  
 100 uL of solution 1 was added to each tube to resuspend the pellets. 200 uL of solution 2 
was added next and the tubes were mixed by inversion. Solution 3 was then added (150uL) and 
mixed immediately by inversion. This solution was placed in a balanced centrifuge and spun at 
13,000 rpm for 10 minutes. This was done so that the protein and chromosomal DNA would 
form a pellet at the bottom, leaving the plasmid in the supernatant. Isopropanol was added to the 
remaining supernatant, along with glycoblue. This solution was centrifuged to form a pellet of 
the desired DNA. The supernatant was removed and the wanted DNA was suspended using 50 
uL of autoclaved water.  
 10 uL of each of the newly made 9 microfuge tubes (containing wanted DNA suspended 
in water) were taken and digested using previously listed Restriction Digest method. The 
digested DNA was run on an agarose gel (Figure 10).  
 The gel was unusual in that lanes contained 3 bands. I had expected a successful cloning 
lane to have 2 bands and an unsuccessful lane to contain one band. After further analysis, I 
thought that this third band might be a successful clone that was not cut by the restriction 
enzyme. 8 of the 9 lanes contained a band that appeared to be in the correct spot. The only one 
that did not show this band was tube 8. Since it was impossible to determine if this was the 
correct band because I was unable to fully decipher the Kb+ latter because it was so faint, I ran a 
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second gel. This time, during the restriction digest I used excess enzymes and used uncut 
controls in the gel in addition to the newly digested DNA (Figure 11). This revealed that one of 
the three bands on the previous gel could very well be a successful clone. 
 
Figure 10: 1.5% Agarose gel made with TAE and run at 140V for 40 minutes. Ladder was faint and gel was smeared. I assume 




Figure 11: 1.5% Agarose gel made with TAE and run at 140V for 40 minutes 
With the conformation from the second gel that the lowest band may contain a clone of interest, 
tubes 1, 2, 3, 4, 5, 6, 7, and 9 were sent off for sequencing. 
Results 
 
 Of the 8 tubes that were sent off for sequencing, one contained the successful clone (for 
sequence see appendix). Tube 1, the tube containing successful clone, was transformed into 
liquid media, grown up at 37 ̊ C overnight, and saved as a cryovial for future use. 
Discussion and Future Directions 
 
 AT/RT is a devastating disease which all too often takes the lives of children before they 
have even had a chance to live them. It has been found that the severe truncation or lack in INI-1 
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plays a major role in this rare form of pediatric brain tumors. INI-1’s role is still unclear, and it is 
not known whether or not the lack of a functional protein causes the disease, or if the disease 
causes INI-1 to be absent or severely truncated. By successfully cloning a common truncation of 
INI-1, we are one step closer to determining this. Using my clone, along with other clones of 
known truncations and the full length clone, they can be inserted into cells, providing a starting 
place to figure out more about this protein and this disease which will hopefully, years down the 
line, lead to lives being saved. 
  The Ruhl laboratory has now successfully cloned three known truncations of INI-1 as 
well as the full-length INI-1. These clones should now be inserted into AT/RT tumor cells and 
changes should be observed. Several assays should be done including growth and proliferation 
assays and biochemical assays such as an apoptosis assay.  
 I expect that when growth and proliferation assays are done in a side by side comparison 
of a full-length INI-1 control, a vector only control (contains no INI-1), and my truncation clone, 
the cells which contain no INI-1 will continue to grow and proliferate at a high rate similar to 
that seen in patients who have AT/RT. I believe that the protein which will have the full-length 
INI-1reintroduced will have a slowing or even halting of the growth and proliferation of the 
tumor cell.  I hypothesize that the cells which have my truncated INI-1 introduced to them will 
continue to grow and proliferate similar to that of the vector only cell because the tumor 
suppressing part of the protein is on the front half of the protein. While INI-1’s shape and 
function is not known, I believe this based on the trend that patients with this specific truncation 




 This will hopefully help to determine whether or not the lack of or truncation of INI-1 
causes the tumors, or if the tumors causes the truncation and absence. Additionally, this might 
help determine what part of the protein is responsible for specific functions since the three 
truncations we currently have are all different and would in turn offer a different location of the 
gene present.  For example, maybe having the front half of the protein would lead to a normalcy 
and the person would not have tumors, but if you are missing the front portion, it would cause 
the same degree of tumors as if the protein were completely absent. Much more research needs 
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Primer Design INI-1 (186-385) 
 
 DNA Sequence: INI-1 (186-385) 
tgctggtccc catccggctg 
gacatggaga tcgatgggca gaagctgcga gacgccttca cctggaacat gaatgagaag 
ttgatgacgc ctgagatgtt ttcagaaatc ctctgtgacg atctggattt gaacccgctg 
acgtttgtgc cagccatcgc ctctgccatc agacagcaga tcgagtccta ccccacggac 
agcatcctgg aggaccagtc agaccagcgc gtcatcatca agctgaacat ccatgtggga 
aacatttccc tggtggacca gtttgagtgg gacatgtcag agaaggagaa ctcaccagag 
aagtttgccc tgaagctgtg ctcggagctg gggttgggcg gggagtttgt caccaccatc 
gcatacagca tccggggaca gctgagctgg catcagaaga cctacgcctt cagcgagaac 
cctctgccca cagtggagat tgccatccgg aacacgggcg atgcggacca gtggtgccca 
ctgctggaga ctctgacaga cgctgagatg gagaagaaga tccgcgacca ggacaggaac 
acgaggcgga tgaggcgtct tgccaacacg gccccggcct gg 
 











Primer (without Restriction Sites):  
 
F: ACG ACC AGG GGT AGG CCG 
  
R: TTG TGC CGG GGC CGG ACC 
 
Primer (With Restriction Sites): 
 









INI-1 (186-385) Clone Sequence: 
 



















Primer: pBABE-R plasmid clone Sequenced: #1 
GTGAAAGGACTCGATGGTGACTCCCGATTCTTACCAGGCCGGGGCCGTGTTGGCAAGACGCCTCATCCGCCTCGT
GTTCCTGTCCTGGTCGCGGATCTTCTTCTCCATCTCAGCGTCTGTCAGAGTCTCCAGCAGTGGGCACCACTGGTCCG
CATCGCCCGTGTTCCGGATGGCAATCTCCACTGTGGGCAGAGGGTTCTCGCTGAAGGCGTAGGTCTTCTGATGCCA
GCTCAGCTGTCCCCGGATGCTGTATGCGATGGTGGTGACAAACTCCCCGCCCAACCCCAGCTCCGAGCACAGCTTC
AGGGCAAACTTCTCTGGTGAGTTCTCCTTCTCTGACATGTCCCACTCAAACTGGTCCACCAGGGAAATGTTTCCCAC
ATGGATGTTCAGCTTGATGATGACGCGCTGGTCTGACTGGTCCTCCAGGATGCTGTCCGTGGGGTAGGACTCGAT
CTGCTGTCTGATGGCAGAGGCGATGGCTGGCACAAACGTCAGCGGGTTCAAATCCAGATCGTCACAGAGGATTTC
TGAAAACATCTCAGGCGTCATCAACTTCTCATTCATGTTCCAGGTGAAGGCGTCTCGCAGCTTCTGCCCATCGATCT
CCATGTCCAGCCGGATGGGGACCAGGGATCCGGCCGGCGCCTAGAGAAGGAGTGAGGGCTGGATAAAGGGAGG
ATCGAGGCGGGGTCGAACGAGGAGGTTCAAGGGGGAGAGACGGGGCGGATGGAGGAAGAGGAGGCGGAGGC
TTAGGGTGTACAAAGGGCTTGACCCAGGGAGGGGGGTCAAAAGCCAAGGCTTCCCAGGTCACGATGTATGGGAC
CTGGTCTGGGTGTCCATGCGGGCCAGGTGAAAAGACCTTGATCTTAACCTGGGTGATGAGGTCTCGGTTAAAGGT
GCCGTCTCGCGGCCATCCGACGTTAAAGGTTGGCCATTCTGCAGAGCAGAAGGTAACCCAACGTCTCTTCTTGACA
TCTACCGACTGGTTGTGAGCGATCCGCTCGACATCTTTCCAGTGACCTAACGTCAACTTAAGGGAGTGGTAACAGT
CTGGCCCTATTTTCAGAACAATACAGGAAAACACAGGTCAGACGAGACAACACAGACGATGCTGCAGCGCTGCAG
CAGAACAAGAACGCGCGGCTCGATCCAACCGAAGCAAATTCGACGAGCGGAAGCTGTTTTAGCTTCTCGATCTCC
TAACCCGGAAGCCCACAGAC 
